口腔黏膜給藥系統市場規模、佔有率和成長分析：按劑型、藥物類型、應用、釋放類型、最終用戶、分銷管道和地區分類－2026-2033年產業預測

2024 年全球口腔黏膜給藥系統市場價值為 56 億美元，預計到 2025 年將成長至 60.5 億美元，到 2033 年將成長至 112.9 億美元，在預測期（2026-2033 年）內複合年成長率為 8.1%。

受人口結構變化和慢性病盛行率上升的推動，全球口腔黏膜給藥系統市場正經歷顯著成長。這些因素刺激了對非侵入性且病人友善的給藥方式的需求。這一創新領域已從傳統片劑發展到薄膜、黏膜貼片和奈米顆粒增強基質等先進劑型，從而最佳化藥物吸收並避免首過代謝。黏膜附著性聚合物黏膜的停留時間和提高其滲透性，進一步加速了市場擴張。因此，在以患者為中心的製劑研發的監管激勵措施和臨床試驗增加的支持下，各公司正積極投資於口腔給藥平台的產品開發，例如Fentanyl口腔片劑和實驗性胰島素貼片，從而在全球範圍內創造了廣泛的許可和生產機會。

全球口腔粘膜給藥系統市場的成長要素

由於其非侵入性給藥的優勢，全球口腔黏膜給藥系統市場正在成長。這種方法提高了患者的依從性，並成為注射和複雜口服給藥方式的理想替代方案。此方法允許藥物直接透過黏膜吸收，從而減少全身副作用，防止胃腸道分解，並提高敏感化合物的治療效果穩定性。簡化的自我給藥流程和更高的患者舒適度進一步促進了參與慢性病管理的臨床醫生和看護者對該技術的接受度。因此，更廣泛的應用正在推動不同醫療機構的需求，這顯著促進了整體市場的擴張。

全球口腔黏膜給藥系統市場的限制因素

全球口腔黏膜給藥系統市場面臨許多挑戰，主要原因在於此類產品核准流程複雜。嚴格的監管要求導致研發週期延長，因為研發人員必須提交關於黏膜安全性和局部刺激性的具體數據。這給申辦者帶來了不確定性，尤其是在區域標準不一且缺乏特定口腔製劑先例的地區。因此，複雜的監管環境增加了研發風險，並可能阻礙中小企業開發創新型口腔黏膜藥物候選產品。這種情況最終會阻礙商業化進程，即使具有科學基礎和潛在的臨床效益，也限制了新產品的市場供應。

口腔黏膜給藥系統的全球市場趨勢

全球口腔給藥系統市場正呈現以病人為中心的製劑創新趨勢。各公司越來越重視透過先進技術（例如口味掩蔽和簡化給藥方案）來提高患者的舒適度和依從性。這一轉變得益於黏膜黏附輔料的改進和獨立給藥形式的普及，從而提高了兒童和老年人群的接受度。此外，透過與人體工學專家合作進行感官評估和包裝設計，這些系統的實際療效也得到了提升。這種對患者需求的關注正在推動產品的持續差異化和改進，使口腔給藥系統成為更切實可行的治療給藥選擇。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢
• 價值鏈分析
• 案例研究
• 技術評估
• 客戶和採購標準分析
• 管道分析
• 疾病流行病學

全球口腔黏膜給藥系統市場規模：依劑型分類

• 用於口腔黏膜的片劑
• 用於口腔黏膜的薄膜
• 頰黏膜斑塊
• 頰黏膜噴霧
• 頰黏膜凝膠
• 其他

全球口腔黏膜給藥系統市場規模：依藥物類型分類

• 止痛藥
• 荷爾蒙
• 循環系統藥物
• 中樞神經系統（CNS）藥物
• 戒菸藥物
• 其他

全球口腔黏膜給藥系統市場規模：依應用領域分類

• 疼痛管理
• 荷爾蒙補充療法
• 心血管疾病
• 神經病變
• 禁止抽煙
• 其他

全球口腔黏膜給藥系統市場規模：依釋放類型分類

• 立即發布
• 緩釋型

全球口腔黏膜給藥系統市場規模：依最終用戶分類

• 醫院
• 診所
• 居家照護環境

全球口腔黏膜給藥系統市場規模：依分銷管道分類

• 醫院藥房
• 零售藥房
• 網路藥房

全球口腔黏膜給藥系統市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Viatris
• Aquestive Therapeutics
• IntelGenx Technologies
• Cure Pharmaceutical
• AdhexPharma
• Tapemark
• ARx LLC
• Kindeva Drug Delivery
• LTS Lohmann Therapie-Systeme
• ZIM Laboratories
• Aphios Corporation
• NemuBio
• Aveva Drug Delivery Systems
• MedRx Co.
• Ensysce Biosciences
• Collegium Pharmaceutical
• Aquestive Therapeutics Technologies
• BioXcel Therapeutics
• Aquestive Therapeutics Manufacturing
• Cipla

結論與建議

Global Buccal Drug Delivery Systems Market size was valued at USD 5.60 Billion in 2024 and is poised to grow from USD 6.05 Billion in 2025 to USD 11.29 Billion by 2033, growing at a CAGR of 8.1% during the forecast period (2026-2033).

The global buccal drug delivery systems market is witnessing significant growth driven by a demographic shift and an increasing prevalence of chronic diseases, which stimulate demand for non-invasive, patient-friendly administration methods. This innovative landscape has evolved from traditional tablets to advanced formats like thin films, mucoadhesive patches, and nanoparticle-enhanced matrices, optimizing drug absorption while circumventing first-pass metabolism. Recent advancements in mucoadhesive polymers and permeation enhancers have further catalyzed market expansion by enhancing drug residence time and permeability through the buccal mucosa. As a result, companies are actively investing in buccal platforms to develop products such as fentanyl buccal tablets and experimental insulin patches, supported by regulatory incentives for patient-focused formulations and increased clinical trials, creating extensive opportunities in licensing and manufacturing globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Buccal Drug Delivery Systems market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Buccal Drug Delivery Systems Market Segments Analysis

Global buccal drug delivery systems market is segmented by dosage form, drug type, application, release type, end user, distribution channel and region. Based on dosage form, the market is segmented into buccal tablets, buccal films, buccal patches, buccal sprays, buccal gels and others. Based on drug type, the market is segmented into analgesics, hormones, cardiovascular drugs, CNS drugs, smoking cessation drugs and others. Based on application, the market is segmented into pain management, hormone replacement therapy, cardiovascular disorders, neurological disorders, smoking cessation and others. Based on release type, the market is segmented into Immediate release and controlled release. Based on end user, the market is segmented into hospitals, clinics and homecare settings. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Buccal Drug Delivery Systems Market

The Global Buccal Drug Delivery Systems market is experiencing growth due to the advantages of noninvasive administration that enhance patient compliance, offering a preferable alternative to injections and intricate oral regimens. This method allows for direct mucosal absorption, which can mitigate systemic side effects, prevent gastrointestinal degradation, and provide improved therapeutic consistency for sensitive compounds. The simplified self-administration process and increased comfort perceived by patients further encourage acceptance among clinicians and caregivers involved in chronic disease management. Consequently, this supports broader implementation and drives demand across various healthcare environments, ensuring a significant impact on overall market expansion.

Restraints in the Global Buccal Drug Delivery Systems Market

The Global Buccal Drug Delivery Systems market faces significant challenges primarily due to the convoluted approval processes associated with these products. Stringent regulatory requirements necessitate extensive development timelines, as developers must provide specific data on mucosal safety and local irritation. This creates uncertainty for sponsors, particularly when dealing with varying standards across different regions and the lack of established precedents for certain buccal formulations. Consequently, the intricate regulatory landscape heightens development risks and may deter smaller companies from pursuing innovative buccal candidates. This situation ultimately hampers commercialization efforts, restricting the availability of new products in the market despite their scientific viability and potential clinical benefits.

Market Trends of the Global Buccal Drug Delivery Systems Market

The Global Buccal Drug Delivery Systems market is witnessing a significant trend towards patient-centric formulation innovation. Companies are increasingly prioritizing formulations that enhance patient comfort and adherence through advanced techniques such as taste-masking and simplified dosing regimens. This shift is contributing to higher adoption rates among pediatric and geriatric populations, driven by improvements in mucoadhesive excipients and discreet delivery formats. Moreover, sensory profiling and collaborative packaging design with human factors experts are enhancing the real-world effectiveness of these systems. This focus on patient needs is fostering iterative product differentiation and refinement, positioning buccal delivery systems as a more viable option in therapeutic administration.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Value Chain Analysis
• Case Studies
• Technology Assessment
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Buccal Drug Delivery Systems Market Size by Dosage Form & CAGR (2026-2033)

• Market Overview
• Buccal Tablets
• Buccal Films
• Buccal Patches
• Buccal Sprays
• Buccal Gels
• Others

Global Buccal Drug Delivery Systems Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Analgesics
• Hormones
• Cardiovascular Drugs
• CNS Drugs
• Smoking Cessation Drugs
• Others

Global Buccal Drug Delivery Systems Market Size by Application & CAGR (2026-2033)

• Market Overview
• Pain Management
• Hormone Replacement Therapy
• Cardiovascular Disorders
• Neurological Disorders
• Smoking Cessation
• Others

Global Buccal Drug Delivery Systems Market Size by Release Type & CAGR (2026-2033)

• Market Overview
• Immediate Release
• Controlled Release

Global Buccal Drug Delivery Systems Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Homecare Settings

Global Buccal Drug Delivery Systems Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Buccal Drug Delivery Systems Market Size & CAGR (2026-2033)

• North America (Dosage Form, Drug Type, Application, Release Type, End User, Distribution Channel)
  • US
  • Canada
• Europe (Dosage Form, Drug Type, Application, Release Type, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Dosage Form, Drug Type, Application, Release Type, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Dosage Form, Drug Type, Application, Release Type, End User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Dosage Form, Drug Type, Application, Release Type, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Viatris
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aquestive Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IntelGenx Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cure Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AdhexPharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tapemark
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ARx LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kindeva Drug Delivery
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LTS Lohmann Therapie-Systeme
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ZIM Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aphios Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NemuBio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aveva Drug Delivery Systems
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MedRx Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ensysce Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Collegium Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aquestive Therapeutics Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioXcel Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aquestive Therapeutics Manufacturing
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations